spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  metastatic melanoma 

 HSMN NewsFeed - 9 Sep 2021
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Feb 2021
OncoSec Strengthens Management Team With Two New Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Dec 2020
AIVITA Biomedical Closes $25 Million Financing Round
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 2 Sep 2019
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki
Biopharmaceuticals Drug Delivery Oncology Acquisitions
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jun 2019
Pfizer to Acquire Array BioPharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 31 May 2019
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Apr 2019
OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO(TM) in Refractory Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Aug 2018
OncoSec Appoints Alain Algazi, MD, as Clinical Strategic Advisor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Aug 2018
IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer; Names William Strohl, Ph.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Jul 2018
OncoSec Appoints Robert W. Ashworth, Ph.D. as Vice President, Regulatory
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jul 2018
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jun 2018
Avella Selected by Array BioPharma Inc. to distribute BRAFTOVI(TM) (encorafenib) and MEKTOVI(R) (binimetinib)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 14 Jun 2018
Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Feb 2018
Partner Therapeutics (PTx) Acquires Leukine(R) from Sanofi
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 22 Dec 2017
Novartis' combination therapy Tafinlar(R) + Mekinist(R) granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Dec 2017
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Oct 2017
OncoSec Presents Positive Phase 2 Data for ImmunoPulse(R) IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2017
Biocept Launches Liquid Biopsy Test for NRAS Mutations
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Dec 2016
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Sep 2016
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jun 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2016
OncoSec Announces $10 Million At-The-Market Registered Direct Offering
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 28 Mar 2016
Lion Biotechnologies Names Michael T. Lotze Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Feb 2016
Collaboration led by ImmunID Awarded Innovate UK Grant to Advance Program on Prediction of Response to Cancer Immunotherapy using ImmunTraCkeR(R)
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 4 Feb 2016
Lion Biotechnologies Names Steven A. Fischkoff Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Dec 2015
European Commission Approves Amgen's IMLYGIC(TM) (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Oct 2015
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Biopharmaceuticals Oncology Dermatology
 HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jul 2015
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Jul 2015
Provectus Biopharmaceuticals Signs Letter of Intent with Boehringer Ingelheim (China) to Collaborate in Bringing PV-10 to Market in China
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 8 May 2015
Provectus Biopharmaceuticals Updates Market on Business Developments
Biopharmaceuticals Dermatology Oncology
 HSMN NewsFeed - 24 Apr 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Feb 2015
FDA Grants Genentech’s Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Sep 2014
OncoSec Medical Appoints Dr. Mai H. Le to Position of Chief Medical Officer and Names Dr. Robert H. Pierce as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2014
Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf(R) (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2014
Guardant Health Announces US Commercial Launch of Guardant360(TM): A Breakthrough Blood Test for Real-Time Cancer Patient Treatment Management
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 27 May 2014
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2014
Provectus Biopharmaceuticals Inc. Appoints Jacob M. Plotsker to Strategic Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 May 2014
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2014
OncoSec Medical Names Adil Daud, M.D. as Chief Clinical Strategist
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Apr 2014
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Jan 2014
Lion Biotechnologies Appoints James Bender, Ph.D., as Vice President, Product Development and Manufacturing
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Dec 2013
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
Biopharmaceuticals Dermatology Oncology
 HSMN NewsFeed - 6 Nov 2013
Lion Biotechnologies Completes $23.3 Million Private Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Sep 2013
Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2012
OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Oct 2012
FDA Approves ABRAXANE(R) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jul 2012
Delcath Announced Changes To Board Of Directors
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 18 Jun 2012
Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
Devices Drug Delivery Oncology
 HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2012
Delcath Announces Agreement With Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital for Training and Launch of Hepatic Chemosat Delivery System
Devices Drug Delivery Oncology
 HSMN NewsFeed - 5 Apr 2012
Delcath Receives European Regulatory Approval for Second Generation Hemofiltration Cartridge
Devices Regulatory
 HSMN NewsFeed - 26 Mar 2012
Delcath Expands Global Marketing Team With Key Pharma Oncology Hire
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 19 Mar 2012
Delcath Announces Agreement with Instituto Oncologico Baselga for Launch of CHEMOSAT in Spain
Devices Drug Delivery Oncology
 HSMN NewsFeed - 9 Mar 2012
Delcath Selects Quintiles to Support EU Launch of CHEMOSAT
Devices Drug Delivery Oncology
 HSMN NewsFeed - 27 Feb 2012
Delcath Announces First CHEMOSAT Procedures in Germany
Devices Drug Delivery Oncology
 HSMN NewsFeed - 20 Feb 2012
Plexxikon Announces European Approval of Zelboraf(R) for the Treatment of Patients With BRAF Mutation-Positive Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Feb 2012
Delcath Appoints Industry Veteran Chris Houchins as Senior Vice President of Clinical and Medical Affairs
Devices Drug Delivery Personnel
 HSMN NewsFeed - 26 Sep 2011
Delcath Expands Senior Management Team
Biopharmaceuticals Devices Drug Delivery Personnel
 HSMN NewsFeed - 17 Aug 2011
FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer
Biopharmaceuticals Oncology Personalized Medicine FDA
 HSMN NewsFeed - 28 Jul 2011
Polaris Group Doses First Patient in Pivotal Phase 3 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 for the Treatment of Hepatocellular Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2011
Genesis Biopharma Names Martin Schroeder to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Jun 2011
Galectin Therapeutics Announces the Appointment of Kevin Freeman and John Mauldin to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 May 2011
Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 13 Apr 2011
Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT Delivery System
Devices Drug Delivery Oncology Regulatory
 HSMN NewsFeed - 4 Apr 2011
Daiichi Sankyo Completes Plexxikon Acquisition
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Mar 2011
Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint of Improvement in Overall Survival in Previously-Untreated Patients with Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2011
Delcath Systems Receives Refusal to File Letter From FDA
Devices Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 27 Jan 2011
REMOXY New Drug Application Accepted by FDA
Biopharmaceuticals Pain Management
 HSMN NewsFeed - 19 Jan 2011
Genentech Personalized Investigational Medicine Shows Survival Benefit in Advanced Skin Cancer
Biopharmaceuticals Diagnostics Personalized Medicine
 HSMN NewsFeed - 22 Dec 2010
Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
Biopharmaceuticals Devices Drug Delivery Oncology FDA
 HSMN NewsFeed - 13 Dec 2010
Lilly Suspends Phase III Trial in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2010
BioVex Commences OncoVEXGM-CSF Phase 3 Trial in Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2010
Delcath Submits CE Mark Technical File for Hepatic ChemoSAT Delivery System
Devices Drug Delivery Oncology Regulatory
 HSMN NewsFeed - 1 Dec 2010
Delcath Names Bernard R. Tyrrell as Senior Vice President for North American Sales and Marketing
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 7 Sep 2010
Bristol-Myers Squibb to Acquire ZymoGenetics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Aug 2010
Ipilimumab Receives FDA Priority Review Designation for Adult Patients with Previously Treated Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Jul 2010
Provectus Pharmaceuticals Reports Achieved Milestones for First Half of 2010, Recent Developments and Plans for the Remainder of the Year to Shareholders
Biopharmaceuticals Dermatology Oncology
 HSMN NewsFeed - 14 Jul 2010
Douglas G. Watson, Former CEO of Novartis Corporation, Joins Delcath Board of Directors
Devices Drug Delivery Personnel
 HSMN NewsFeed - 1 Jul 2010
BioVex Appoints Steven Kelly as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jun 2010
Myriad Pharmaceuticals Announces Intent to Focus on Oncology Portfolio
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2010
Delcath Systems Appoints Peter J. Graham as Executive Vice President and General Counsel
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 19 Apr 2010
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Apr 2010
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Mar 2010
Delcath Systems Provides Update on Corporate Developments
Devices Oncology Drug Delivery
 HSMN NewsFeed - 1 Mar 2010
Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
Devices Oncology Drug Delivery Personnel
 HSMN NewsFeed - 26 Jan 2010
Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 4 Jan 2010
BioVex Appoints Tim Hanke as VP Commercial Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Dec 2009
Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Nov 2009
Delcath Systems Reports Substantial Progress
Devices Oncology
 HSMN NewsFeed - 5 Nov 2009
ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Oct 2009
Antigenics Announces a Negative Vote From the CHMP on Oncophage(R) Marketing Application in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Aug 2009
Patients Begin Enrolling into Investigator-Sponsored Phase 2 Trial of Antigenics' Oncophage(R) Cancer Vaccine in Newly Diagnosed Glioma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jul 2009
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Biopharmaceuticals
 HSMN NewsFeed - 29 Apr 2009
FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Mar 2009
BioVex Raises $40 Million in First Close of Series F Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 13 Mar 2009
Synta Restructures Organization to Focus on New Priorities
Biopharmaceuticals
 HSMN NewsFeed - 22 Dec 2008
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Nov 2008
Delcath Systems Granted Orphan-Drug Designations for Cutaneous and Ocular Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Sep 2008
FDA Grants Permission For Export of Antigenics' Oncophage(R) to Russia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Aug 2008
Pain Therapeutics and King Pharmaceuticals Announce Final Data of REMOXY Phase III Study at World Pain Congress in Scotland
Biopharmaceuticals
 HSMN NewsFeed - 5 Aug 2008
Curacyte Sells Its Subsidiary Curacyte Discovery GmbH to The Medicines Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Aug 2008
The Medicines Company Acquires CU-2010 and Curacyte Discovery GmbH
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Aug 2008
TVM Capital Welcomes The Medicines Company in The European Market Through the Acquisition of Curacyte Discovery GmbH
Biopharmaceuticals Venture Capital Mergers & Acquisitions
 HSMN NewsFeed - 28 Jul 2008
Nexavar Approved for Liver Cancer in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Jul 2008
PhiloGene, Inc. Announces that VEGFb(TM) has been Granted Orphan Drug Designation by the FDA for the Treatment of Advanced Melanoma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 14 Jul 2008
Synta Pharmaceuticals Names Michael P. Bailey Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2008
FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
Biopharmaceuticals Radiology FDA
 HSMN NewsFeed - 7 Jul 2008
Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Jun 2008
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
Biopharmaceuticals
 HSMN NewsFeed - 3 Jun 2008
Provectus Pharmaceuticals Appoints Kelly M. McMasters, MD, PhD, to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2008
BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2008
New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2008
Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2008
Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Devices Drug Delivery Oncology
 HSMN NewsFeed - 16 May 2008
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2008
CuraGen Sells Ownership of Belinostat to TopoTarget A/S
Biopharmaceuticals
 HSMN NewsFeed - 8 Apr 2008
Oncophage(R) Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Apr 2008
Medarex Announces Ipilimumab Program Continues to Move Forward
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Mar 2008
Morphotek(R) Signs Exclusive Licensing Agreement for Anti-Cancer Antibody
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jan 2008
Synta and GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designation by the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jan 2008
Kosan Appoints Helen S. Kim as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Dec 2007
Actelion Provides Update On Bosentan in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2007
Remoxy Meets Primary Endpoint in Pivotal Phase III Study
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2007
AVAX Technologies Appoints Dr. Francois Martelet as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Nov 2007
Delcath Resumes Enrollment in Phase III and Phase II Trials
Devices Drug Delivery Oncology FDA
 HSMN NewsFeed - 13 Nov 2007
AVAX Technologies announces the initiation of its Phase III Registration trial of M-Vax(R) in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2007
Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2007
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2007
Data from Investigator-Sponsored Trial of Oncophage(R) Cancer Vaccine in Glioma Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Oct 2007
GlaxoSmithKline and Synta Pharmaceuticals Announce Development and Commercialization Collaboration for STA-4783 in Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Oct 2007
Delcath Systems Issues CEO Letter to Shareholders
Devices Drug Delivery Oncology
 HSMN NewsFeed - 19 Sep 2007
CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Aug 2007
Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Aug 2007
GammaCan Receives FDA Orphan Drug Designation for Lead Product VitiGam(TM) for Stage IIB to Stage IV Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Biopharmaceuticals
 HSMN NewsFeed - 2 Aug 2007
Antigenics Provides Update on Filing for Approval of Oncophage(R) in Russia for the Treatment of Intermediate-Risk Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jul 2007
Point Therapeutics Update
Biopharmaceuticals
 HSMN NewsFeed - 11 Jul 2007
Patient Recruitment Completed for Pivotal Phase III Study of Remoxy
Biopharmaceuticals Pain Management
 HSMN NewsFeed - 9 Jul 2007
BioVex Raises $22 Million in First Close of Series E Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Patients Who Took Investigational Melanoma Compound CP-675,206 Showed Favorable Survival Outcomes, Pfizer Says
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
Point Therapeutics Reduces Costs by Cutting Work Force
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
Delcath Systems Receives National Cancer Institute Approval to Expand Phase III Trial to Multiple Centers
Devices Drug Delivery Oncology
 HSMN NewsFeed - 21 May 2007
Talabostat Clinical Program Put on Clinical Hold by FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2007
Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Apr 2007
Data from Investigator-Sponsored Trial of Oncophage(R) Cancer Vaccine in Glioma Presented at American Association of Neurological Surgeons Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2007
Synta Pharmaceuticals Corp. Strengthens Oncology Clinical and Commercial Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Metastatic Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2007
Pain Therapeutics Licenses Biotechnology To Treat Rare Disorder
Biopharmaceuticals Licensing
 HSMN NewsFeed - 22 Mar 2007
Eisai To Acquire Morphotek
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 1 Mar 2007
Point Therapeutics Provides Clinical Update
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2007
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2007
Point Therapeutics Announces Resignation of William Whelan from Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jan 2007
Vical Highlights Transition to Phase 3 Trial With Allovectin-7(R) for Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jan 2007
Point Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer Study
Biopharmaceuticals
 HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jan 2007
Provectus Receives Orphan Drug Designation from FDA for Anti-Cancer Agent PV-10 for the Treatment Of Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jan 2007
Vical Initiates Pivotal Phase 3 Trial of Allovectin-7(R) as First-line Therapy for Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jan 2007
Medarex Announces Enrollment Complete in Ipilimumab (MDX-010) Monotherapy Pivotal Registrational Trial for Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2006
Pain Therapeutics Initiates Phase III Study With Oxytrex(TM)
Biopharmaceuticals
 HSMN NewsFeed - 7 Dec 2006
Medarex Announces FDA Fast Track Designations for Ipilimumab for the Treatment of Metastatic Melanoma; Fast Track Designations for First-Line Use in Combination With Chemotherapy and Second-Line Use as Monotherapy
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2006
AVAX Technologies Launches Global Phase III Registration Clinical Trial of M-Vax in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2006
Genta Initiates Pilot Clinical Trial of Genasense(R) Plus Abraxane(R) and Temodar(R) as First-Line Therapy for Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Nov 2006
Synta Pharmaceuticals Announces FDA Fast Track Designation for STA-4783 in Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Oct 2006
GammaCan International, Announces Appointment of Lynn Schuchter M.D. to its Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Oct 2006
AVAX Technologies Announces Special Protocol Assessment Agreement with FDA for a Phase III Clinical Trial of M-Vax in Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Aug 2006
Celator Pharmaceuticals Names Dr. Arthur C. Louie as New Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Jun 2006
Nexavar Receives Fast Track Designation from the FDA for Metastatic Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jun 2006
Clinical Data on Volociximab (M200) Presented at the American Society of Clinical Oncology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2006
Updated Overall Survival Analysis Presented on Nexavar Phase III Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2006
Point Therapeutics Receives Fast Track Designation for Talabostat
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 May 2006
Long-Term Results from TNFerade(TM) Pancreatic Cancer Study and Updated Survival Results from TNFerade(TM) Esophageal Cancer Study Both Reported at Digestive Disease Week
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 May 2006
Enrollment Completed in Phase III Studies of Nexavar for Patients With Metastatic Melanoma and Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Apr 2006
Nexavar(R) Receives Positive Opinion from European Committee for Medicinal Products for Human Use
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Apr 2006
FDA Grants Orphan Drug Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Apr 2006
European Commission Grants Orphan Medicinal Product Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Apr 2006
Point Therapeutics to Present Novel Dual Mechanism of Action for Talabostat During Research and Development Day on April 25
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Mar 2006
Medarex Announces Initiation of Registrational Trial for Ipilimumab (MDX-010) as Monotherapy in Previously-Treated Metastatic Melanoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Mar 2006
Nexavar Approved in Switzerland for the Treatment of Patients with Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Mar 2006
GenVec Begins Phase II Melanoma Study with TNFerade(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Mar 2006
CancerVax Announces Results of Phase 3 Clinical Trials of Canvaxin(TM) in Patients With Stage III and Stage IV Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2006
Delcath Systems Receives Special Protocol Assessment and Agreement from FDA
Devices Drug Delivery Oncology FDA
 HSMN NewsFeed - 16 Feb 2006
Bayer and Onyx Initiate Phase III Non-Small Cell Lung Cancer Trial Studying Nexavar (sorafenib) Tablets in Combination With Two Chemotherapeutic Agents
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2006
Delcath Systems Receives NCI Institutional Review Board Approval
Devices Drug Delivery Oncology
 HSMN NewsFeed - 2 Feb 2006
Analysis of Genasense(R) Trial Confirms Major Efficacy Variables in Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Feb 2006
Genasense(R) Marketing Authorization Application in Melanoma Accepted for Review by European Regulatory Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Jan 2006
Gammacan to Explore the Efficacy of IVIg sourced from Specific Population for the Treatment of Malignant Melanoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2006
Long-Term Survival Data from Genvec's Phase II Study of TNFerade(TM) in Esophageal Cancer Presented at ASCO GI
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jan 2006
Provectus CEO Issues Open Letter to Shareholders
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 108

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 108 additional stories matching:
metastatic melanoma
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.